Background: Carcinomas of unknown primary (CUP) account for approximately 2-5% of all cancer diagnoses. Except for some subsets with favorable prognosis, for most of these patients treatment options are limited, and no standard first-line regimen has been identified. We performed a phase II study with oxaliplatin (OX) and capecitabine (CAP) as first-line treatment for patients with histo-or cytologically proven adeno- or undifferentiated CUP.
Patients And Methods: Protocol treatment in this multicenter trial consisted of CAP 1,000 mg/m(2) twice daily orally (days 1-14) and OX 130 mg/m(2) intravenously (day 1), repeated every 21 days at a maximum of 6 cycles. The primary endpoint was the response rate (RR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and safety.
Results: 51 patients with CUP (71% with poorly differentiated adenocarcinoma; 41% ECOG performance status (PS) 0, 39% PS 1, 10% PS 2, 55% with elevated lactate dehydrogenase (LDH), and 39% with liver metastases) were enrolled in this study. We observed an objective RR of 11.7% and a median PFS of 2.5 months as well as an OS of 7.5 months with a good toxicity profile.
Conclusion: CAP/OX did not reach higher RR compared to a standard regimen with paclitaxel/carboplatin, which discourages further investigation of this schedule in CUP.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000201125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nasal Cavity and Paranasal Sinus Cancer: Diagnosis and Treatment.
Curr Oncol Rep
September 2024
Social Medicine and Public Health, Department for Health Promotion and Monitoring of Diseases, Institute of Public Health of the Republic of North Macedonia, 50 Divizija No.6, Skopje, 1000, North Macedonia.
Purpose Of Review: The purpose of this review is to analyze the diagnosis and treatments of the sinonasal malignant tumors throw systematic reviewed literature. The systematic review of the literature was performed according to PRISMA guidelines.
Recent Findings: Total 11,653 cases of five article were analyzed.
Evaluation of the SH-SY5Y cell line as an model for potency testing of a neuropeptide-expressing AAV vector.
Front Mol Neurosci
November 2023
Department of Neurology, AG Gene Therapy, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Viral vectors have become important tools for basic research and clinical gene therapy over the past years. However, testing of vector-derived transgene function can be challenging when specific post-translational modifications are needed for biological activity. Similarly, neuropeptide precursors need to be processed to yield mature neuropeptides.
View Article and Find Full Text PDF[Effects of small GTP-binding protein GDP dissociation stimulator on adipocyte hypertrophy and glucose metabolism disorder in mice].
Zhonghua Nei Ke Za Zhi
June 2023
Department of Cardiology, The Hospital Affiliated to Medical School of Yangzhou University (Taizhou People's Hospital), Taizhou 225300, China.
To explore the effect and mechanism of small GTP-binding protein GDP dissociation stimulator (SmgGDS) on the development of obesity. (1) 8-week-old C57BL/6J mice were randomly assigned to normal diet and high fat diet group, with 6 mice in each group. They were fed regular feed and a high fat diet containing 60% fat for 4 months, respectively.
View Article and Find Full Text PDFChemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism.
Sci Rep
May 2023
Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, 46202, USA.
Although more adeno-associated virus AAV-based drugs enter the clinic, vector tissue tropism remains an unresolved challenge that limits its full potential despite that the tissue tropism of naturally occurring AAV serotypes can be altered by genetic engineering capsid vie DNA shuffling, or molecular evolution. To further expand the tropism and thus potential applications of AAV vectors, we utilized an alternative approach that employs chemical modifications to covalently link small molecules to reactive exposed Lysine residues of AAV capsids. We demonstrated that AAV9 capsid modified with N-ethyl Maleimide (NEM) increased its tropism more towards murine bone marrow (osteoblast lineage) while decreased transduction of liver tissue compared to the unmodified capsid.
View Article and Find Full Text PDFEffects of Recombinant Adeno-Associated Virus-Mediated Overexpression of on the Chondrogenic Fate of Human Bone Marrow-Derived Mesenchymal Stromal Cells.
Hum Gene Ther
September 2022
Center of Experimental Orthopedics, Saarland University and Saarland University Medical Center, Homburg, Germany.
Implantation of genetically modified chondrogenically competent human bone marrow-derived mesenchymal stromal cells (hMSCs) is an attractive strategy to improve cartilage repair. The goal of this study was to examine the potential benefits of transferring a sequence coding for the () that modulates bone and cartilage formation, using recombinant adeno-associated virus (rAAV) vectors on the chondroreparative activities of hMSCs. Undifferentiated and chondrogenically induced primary human MSCs were treated with an rAAV-h construct to evaluate its effects on the proliferative, metabolic, and chondrogenic activities of the cells compared with control (reporter rAAV- vector) condition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!